Israeli drug maker Teva Pharmaceutical Industries Ltd. is in talks to combine with Allergan PLC’s big generic-drug business, in a move that would further consolidation in the health-care industry and likely mean the end of Teva’s pursuit of another acquisition.
A deal for the Allergan business, valued at about $45 billion, could be announced as early as Monday.
Teva has been seeking to buy Mylan NV, a deal Mylan has been resisting as it pursues fellow drug maker Perrigo Co. PLC.
The merger would be the latest to shake up a major sector of the health-care industry, and come on the heels of two big announcements in which four of the largest managed-care companies— Anthem Inc. and Cigna Corp. and Aetna Inc. and Humana Inc.—agreed to combine into two companies, in deals worth a combined $82 billion.
Full content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
